On January 26, the U.S. Food and Drug Administration (FDA) announced on its official website the suspension of the Emergency Use Authorization (EUA) for AstraZeneca's long-acting neutralizing antibody Evusheld. Data shows that Evusheld is unlikely to be effective against certain SARS-CoV-2 variants, which are expected to account for over 90% of current infections in the United States.
Previously, Evusheld received EUA in December 2021 for pre-exposure prophylaxis of COVID-19.